Rezolute Inc. Secures $100 Million in Public Offering Led by Frazier Life Sciences
Rezolute, Inc. (RZLT) announces a $100 million public offering led by Frazier Life Sciences to fund ersodetug commercialization and general corporate purposes.
ALFA USA News
Straight from the SEC filing
Every SEC filing by Rezolute, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (16 Nov 2026). Not a valuation or a recommendation.
Down 3.2% over the last month ($3.70 on 19 Oct → $3.58 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $3.70 |
|---|---|
| 20 Oct | $3.70 |
| 21 Oct | $3.70 |
| 22 Oct | $3.86 |
| 23 Oct | $3.85 |
| 26 Oct | $3.82 |
| 27 Oct | $4.11 |
| 28 Oct | $4.22 |
| 29 Oct | $4.12 |
| 30 Oct | $3.95 |
| 2 Nov | $3.88 |
| 3 Nov | $4.01 |
| 4 Nov | $3.96 |
| 5 Nov | $3.64 |
| 6 Nov | $3.88 |
| 9 Nov | $3.87 |
| 10 Nov | $4.02 |
| 11 Nov | $4.07 |
| 12 Nov | $3.87 |
| 13 Nov | $3.65 |
| 16 Nov | $3.58 |
Rezolute, Inc. (RZLT) announces a $100 million public offering led by Frazier Life Sciences to fund ersodetug commercialization and general corporate purposes.
Rezolute (RZLT) achieves primary endpoint in Phase 3 upLIFT study for ersodetug, with 81% of tumor hyperinsulinism patients reducing IV glucose dependency by 50%.
Track Rezolute, Inc. live
Get the next Rezolute, Inc. SEC filing seconds after it lands.